First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody

Purpose: To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of DS002 injection, an anti-nerve growth factor (anti-NGF) monoclonal antibody for treating pain conditions, in healthy Chinese subjects.Methods: This study was a single-center, randomized, double-blind, single-dose e...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Tingting Ma, Bei Cao, Lei Huang, Yuanxun Yang, Yan Geng, Pinhao Xie, Yu Zhao, Hui Lin, Kun Wang, Chunhe Wang, Runbin Sun, Juan Li
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2022-12-01
Serie:	Frontiers in Pharmacology
Soggetti:	DS002 anti-nerve growth factor antibody first-in-human trial pharmacodynamics novel analgesic
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1075309/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!